PL1649023T3 - Polipeptyd o podwyższonej aktywności deaminazy cytozyny - Google Patents

Polipeptyd o podwyższonej aktywności deaminazy cytozyny

Info

Publication number
PL1649023T3
PL1649023T3 PL04744156T PL04744156T PL1649023T3 PL 1649023 T3 PL1649023 T3 PL 1649023T3 PL 04744156 T PL04744156 T PL 04744156T PL 04744156 T PL04744156 T PL 04744156T PL 1649023 T3 PL1649023 T3 PL 1649023T3
Authority
PL
Poland
Prior art keywords
polypeptide
cytosine deaminase
deaminase activity
improved
activity
Prior art date
Application number
PL04744156T
Other languages
English (en)
Inventor
Philippe Erbs
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of PL1649023T3 publication Critical patent/PL1649023T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/78Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL04744156T 2003-07-21 2004-06-29 Polipeptyd o podwyższonej aktywności deaminazy cytozyny PL1649023T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP03360087 2003-07-21
US50827403P 2003-10-06 2003-10-06
EP04744156A EP1649023B1 (en) 2003-07-21 2004-06-29 Polypeptide having an improved cytosine deaminase activity
PCT/IB2004/002505 WO2005007857A1 (en) 2003-07-21 2004-06-29 Polypeptide having an improved cytosine deaminase activity

Publications (1)

Publication Number Publication Date
PL1649023T3 true PL1649023T3 (pl) 2009-01-30

Family

ID=39719832

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04744156T PL1649023T3 (pl) 2003-07-21 2004-06-29 Polipeptyd o podwyższonej aktywności deaminazy cytozyny

Country Status (16)

Country Link
US (3) US7790445B2 (pl)
EP (2) EP1897938B9 (pl)
JP (1) JP4672659B2 (pl)
KR (1) KR101062140B1 (pl)
CN (1) CN1826410B (pl)
AT (1) ATE405654T1 (pl)
AU (1) AU2004257935B2 (pl)
CA (1) CA2532783C (pl)
CY (1) CY1110397T1 (pl)
DE (1) DE602004015995D1 (pl)
DK (1) DK1649023T3 (pl)
ES (1) ES2311831T3 (pl)
IL (1) IL173158A (pl)
PL (1) PL1649023T3 (pl)
PT (1) PT1649023E (pl)
WO (1) WO2005007857A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2611975T3 (es) 2006-06-20 2017-05-11 Transgene S.A. Procedimiento para producir poxvirus y composiciones de poxvirus
US8361788B2 (en) 2007-07-03 2013-01-29 Transgene S.A. Immortalized avian cell lines comprising E1A nucleic acid sequences
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
CN105624193B (zh) * 2008-09-26 2021-07-13 索元生物医药(美国)有限公司 重组载体
NZ596595A (en) 2009-05-12 2013-05-31 Transgene Sa Method for orthopoxvirus production and purification
IN2012DN01577A (pl) 2009-07-21 2015-06-05 Transgene Sa
EP2527432A1 (en) * 2011-05-23 2012-11-28 Novozymes A/S Bi-directional cytosine deaminase-encoding selection marker
WO2013004658A1 (en) 2011-07-01 2013-01-10 Transgene Sa Formulations of 5-fluorocytosine and uses thereof.
US9642921B2 (en) 2012-12-20 2017-05-09 Tocagen Inc. Cancer combination therapy and recombinant vectors
ES2768715T3 (es) 2014-04-10 2020-06-23 Transgene Vectores oncolíticos poxvíricos
EP3552615B8 (en) 2014-07-16 2022-03-02 Transgene Oncolytic virus for expression of immune checkpoint modulators
AU2015357225B2 (en) 2014-12-01 2020-04-09 Transgene Sa Stable liquid vaccinia virus formulations
ES3011733T3 (en) 2015-02-13 2025-04-08 Transgene Immunotherapeutic vaccine and antibody combination therapy
WO2017135800A1 (ko) * 2016-02-05 2017-08-10 주식회사 에스엘바이젠 Trail 및 cd를 발현하는 중간엽줄기세포 및 이의 용도
EP3452081A1 (en) 2016-05-04 2019-03-13 Transgene SA Combination therapy with cpg tlr9 ligand
US20190336552A1 (en) 2016-05-30 2019-11-07 Astellas Pharma Inc. Genetically engineered vaccinia viruses
PT3480307T (pt) * 2016-05-30 2021-07-26 Nat Univ Corp Tottori Univ Novos vírus da vacina geneticamente modificados
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
WO2019170820A1 (en) 2018-03-07 2019-09-12 Transgene Parapoxvirus vectors
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
MX2021003539A (es) 2018-09-26 2021-05-27 Astellas Pharma Inc Terapia contra el cancer en donde el virus vaccinia oncolitico e inhibidor de punto de control inmunitario se usan en combinacion, y composicion farmaceutica y medicamento de combinacion usado en ella.
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2024038175A1 (en) 2022-08-18 2024-02-22 Transgene Chimeric poxviruses

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
FR2583429B1 (fr) 1985-06-18 1989-11-03 Transgene Sa Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
CA2018273C (en) * 1989-06-09 1999-04-06 Peter D. Senter Thermally stable cytosine deaminase
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
DK0931830T3 (da) 1993-02-16 2001-06-11 Onyx Pharma Inc Cytopatiske vira til terapi og profylakse af neoplasi
AU6953394A (en) * 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5856153A (en) 1994-11-17 1999-01-05 Cayla Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
FR2759382A1 (fr) 1997-02-10 1998-08-14 Transgene Sa Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
FR2762615B1 (fr) 1997-04-28 1999-07-16 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes et vecteur le contenant
FR2777570A1 (fr) * 1998-04-17 1999-10-22 Transgene Sa Mutant ayant une activite phosphoribosyl transferase
US6552005B1 (en) * 1998-09-29 2003-04-22 Uab Research Foundation Molecular chemotherapy enhancement of radiotherapy
US20030121068A1 (en) * 2001-11-30 2003-06-26 Paul Orchard Vector encoding suicide and marker constructs
US7141404B2 (en) * 2002-12-27 2006-11-28 Onyx Pharmaceuticals, Inc. Candida kefyr cytosine deaminase

Also Published As

Publication number Publication date
IL173158A0 (en) 2006-06-11
CA2532783C (en) 2013-09-17
IL173158A (en) 2009-12-24
US8257692B2 (en) 2012-09-04
HK1084150A1 (en) 2006-07-21
ES2311831T3 (es) 2009-02-16
EP1897938A1 (en) 2008-03-12
HK1112024A1 (en) 2008-08-22
CN1826410B (zh) 2011-10-26
CN1826410A (zh) 2006-08-30
KR20060040697A (ko) 2006-05-10
US20100330031A1 (en) 2010-12-30
JP2006527994A (ja) 2006-12-14
PT1649023E (pt) 2008-11-20
DE602004015995D1 (de) 2008-10-02
ATE405654T1 (de) 2008-09-15
US7790445B2 (en) 2010-09-07
AU2004257935A1 (en) 2005-01-27
US20070264235A1 (en) 2007-11-15
US20100330051A1 (en) 2010-12-30
CY1110397T1 (el) 2015-04-29
CA2532783A1 (en) 2005-01-27
EP1897938B1 (en) 2010-10-06
EP1897938B9 (en) 2011-08-31
JP4672659B2 (ja) 2011-04-20
EP1649023A1 (en) 2006-04-26
AU2004257935B2 (en) 2009-11-19
DK1649023T3 (da) 2008-10-06
KR101062140B1 (ko) 2011-09-05
US8226954B2 (en) 2012-07-24
WO2005007857A1 (en) 2005-01-27
EP1649023B1 (en) 2008-08-20

Similar Documents

Publication Publication Date Title
IL173158A0 (en) Polypeptide having an improved cytosine deaminase activity
IN2014CN02050A (pl)
EP1496123A4 (en) ACETOLACTATE SYNTHASE CODING GENES
DK1888761T3 (da) Rekombinante N-glycosylerede proteiner fra prokaryote celler
BRPI0517493A (pt) polinucleotìdeo isolado, promotor vetor de expressão, célula hospedeira e uso de um polinucleotìdeo
PL1601776T4 (pl) Wektory ekspresyjne zawierające promotor mCMV-IE2
WO2008152140A3 (en) Recombinant transferrin mutants
TW200740841A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
DK1240524T3 (da) Cellulase fra T. Reesei med forbedret termostabilitet
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof
TW200621284A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
MX2008002485A (es) Polipeptidos que tienen actividad antimicrobiana y polinucleotidos que los codifican.
DE602007006493D1 (de) Peptide mit proliferationshemmender wirkung
TW200700076A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
TW200621285A (en) Polypeptides having antimicrobial activity and polyncleotides encoding same
WO2003072733A3 (en) Modified bace
ATE496121T1 (de) Lactobacillus fermentum n-desoxyribosyl- transferasen und deren verwendung zur enzymatischen synthese von 2',3'- didesoxynucleosiden und 2',3'-didehydro-2',3'- didesoxynucleosiden
WO2006031993A3 (en) Enhancing recombinant hemoglobin production by co-expression with alpha hemoglobin stabilizing protein
IL152232A0 (en) Promoter to il-18bp, its preparation and use
TW200617021A (en) Isolated photoprotein aequorin y89f, and its use
DE60330140D1 (de) Gen-silencing-vektor und diesen verwendendes gen-silencing-verfahren
WO2006122650A3 (de) Isoliertes photoprotein aqdecay sowie dessen verwendung
EP1467207A4 (en) Screening method
GB2441941A (en) An isolated recombinant vaccinia virus complement control protein (HRVCP) polypeptide
WO2003099995A3 (en) Murine ortholog of the human disrupted-in-schizophrenia 1 gene